Skip to main content

3 Result(s)

within Chaoling Feng Remove this filter

and

  1. Article

    Open Access

    Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor

    Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) often require multiple lines of treatment and have a poor prognosis, particularly after failing covalent Bruton tyrosine kinase inhibitor (cBT...

    Gilles Salles, Jenny M. H. Chen, Ina Zhang, Fabio Kerbauy… in Advances in Therapy (2024)

    Download PDF (900 KB) View Article

  2. No Access

    Article

    Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients

    Brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, is approved for relapsed/refractory B-cell precursor acute lymphoblastic leukemia in adults aged 18+/26+ years i...

    Bijal Shah, Jenny M. H. Chen, James J. Wu, Chaoling Feng, Lang Zhou… in Advances in Therapy (2023)

  3. Article

    Open Access

    Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

    Despite currently available treatments for adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL), survival outcomes remain poor, highlighting the need for new therapeutic strategies. This stud...

    Bijal D. Shah, Nathaniel J. Smith, Chaoling Feng, Sushanth Jeyakumar… in Advances in Therapy (2022)

    Download PDF (818 KB) View Article